跳至主要内容
临床试验/EUCTR2011-002362-21-ES
EUCTR2011-002362-21-ES进行中(未招募)不适用

A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder with inadequate response to antidepressant treatment

H. Lundbeck A/S0 个研究点目标入组 500 人开始时间: 2011年10月28日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ?The patient is a man or woman, between 18 and 75 years old (inclusive)
  • ?The patient is being treated with an SRI antidepressant (monotherapy) that was prescribed to treat Major Depressive Episode (DSM-IV-TR criteria)
  • ?The response to the current SRI treatment is inadequate and patient agrees to discontinue the current SRI at the baseline
  • ?MADRS total score ?22 at the Screening Visit and Baseline
  • ?The patient, if a woman, must: agree not to try to become pregnant during the study, AND use adequate, highly effective contraception
  • Other protocol-defined inclusion criteria may apply
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 395
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 105

排除标准

  • ?The patient has any current Axis I disorders (DSM-IV criteria) other than MDD, GAD and SAD
  • ?The patient is at significant risk of suicide
  • ?The patient is currently receiving formal psychotherapy or otherpsychoactive medications
  • Other protocol-defined exclusion criteria may apply

研究者

相似试验

进行中(未招募)
1 期
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression ( VIVRE )
EUCTR2019-002704-41-ESH. Lundbeck A/S600
进行中(未招募)
1 期
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression ( VIVRE )
EUCTR2019-002704-41-CZH. Lundbeck A/S600
进行中(未招募)
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.-Major Depressive Disorder (MDD)MedDRA version: 14.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2011-002362-21-ATH. Lundbeck A/S500
进行中(未招募)
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.-Major Depressive Disorder (MDD)MedDRA version: 14.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2011-002362-21-BGH. Lundbeck A/S500
进行中(未招募)
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.Major Depressive Disorder (MDD)MedDRA version: 14.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2011-002362-21-ITH.LUNDBECK A/S500